首页> 外文期刊>IBM Journal of Research and Development >Ligand discovery on massively parallel systems
【24h】

Ligand discovery on massively parallel systems

机译:大规模并行系统上的配体发现

获取原文
获取原文并翻译 | 示例
       

摘要

Virtual screening is an approach for identifying promising leads for drugs and is used in the pharmaceutical industry. We present the parallelization of LIDAEUS (Ligand Discovery At Edinburgh UniverSity), creating a massively parallel high-throughput virtual-screening code. This program is being used to predict the binding modes involved in the docking of small ligands to proteins. Parallelization efforts have focused on achieving maximum parallel efficiency and developing a memory-efficient parallel sorting routine. Using an IBM Blue Gene/L~(TM)supercomputer, runtimes have been reduced from 8 days on a modest seven-node cluster to 62 minutes on 1,024 processors using a standard dataset of 1.67 million small molecules and FKBP12, a protein target of interest in immunosuppressive therapies. Using more-complex datasets, the code scales upward to make use of the full processor set of 2,048. The code has been successfully used for the task of gathering data on approximately 1.67 million small molecules binding to approximately 400 high-quality crystallographically determined ligand-bound protein structures, generating data on more than 646 million protein-ligand complexes. A number of novel ligands have already been discovered and validated experimentally.
机译:虚拟筛选是一种用于识别有前途的药物线索的方法,在制药行业中使用。我们介绍了LIDAEUS(爱丁堡大学的配体发现)的并行化,从而创建了大规模并行的高通量虚拟筛选代码。该程序用于预测小配体对接蛋白质时涉及的结合模式。并行化工作集中在实现最大并行效率和开发内存有效的并行排序例程上。使用IBM Blue Gene / L〜™超级计算机,运行时间已从原来的7个节点群集的8天减少到1,024个处理器上的62分钟,使用了167万个小分子和FKBP12(蛋白质目标靶标)的标准数据集在免疫抑制疗法中。使用更复杂的数据集,代码可以向上扩展以利用完整的处理器集2,048。该代码已成功用于收集约167万个小分子数据的任务,这些小分子与约400种高质量的晶体学确定的配体结合的蛋白质结构结合,生成了超过6.46亿个蛋白质-配体复合物的数据。已经发现了许多新颖的配体并通过实验进行了验证。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号